IP Library Patent Application 11603286
Patent Application
App. No. 11/603,286

Novel antibacterial agents

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/603,286
Abstract

This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.

Claims (5)

1 . A multibinding compound which comprises from 2-10 ligands covalently connected by a linker or linkers wherein each of said ligands comprises a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, a pencillinase enzyme, a cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate provided that:

(i) all the ligands in a multibinding compound of Formula (I) cannot be either a beta lactam antibiotic, an optionally substituted glycopeptide antibiotic, or an aglycone derivative of an optionally substituted glycopeptide antibiotic;

(ii) when p is 2 and q is 1 then at least one of the ligands is a beta lactam antibiotic; and

(iii) when p is 2, q is 1, and one of the ligands is vancomycin attached via the [C], then the other cannot be cefalexin attached to the linker via acylation of its alpha amino group.

2 - 40 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033162/0550 →